ANNUAL REPORT 2016
LEAPS AND BOUNDS
Letter from Chair and CEO
As GHIT’s fifth anniversary approaches in 2017, our motivation to accelerate global health R&D is stronger than ever.
We extend our deepest gratitude to the development partners, funders, and sponsors whose creativity, courage, and passion fuel our own.
GHIT COMMITTED INVESTMENT
EXPANDING GLOBAL NETWORK
We advance the global health R&D portfolio by investing in innovations that leverage Japan’s unparalleled resources and know-how, that can be brought to market in the relative near term, and that will have a significant impact on the global disease burden. We use private sector standards for our portfolio management.
GHIT banks on a vibrant ecosystem of cross-sector, cross-border collaboration. Fostering that ecosystem is tremendously important to us. We are proud of the sectoral diversity of our development partnerships, which involve many research institutes, private companies, non-profit organizations, and academic institutions, all helping one another to achieve their respective project goals.
Today, over two billion people lack access to essential medicines. In the poorest parts of Africa and Asia, which bear the brunt of the global infectious disease burden, this figure rises to half of the population. For GHIT, and all its partners, access is inextricably linked to the R&D process.